Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 09/29 10:00:23 am
8540.5 GBX   +0.37%
06:00aASTRAZENECA : Serum Institute to boost production of COVID-19 vaccine doses to 200 million
RE
05:01aASTRAZENECA : Berenberg gives a Buy rating
MD
04:24aASTRAZENECA : JP Morgan reaffirms its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Tagrisso Granted Breakthrough Therapy Designation in U.S.

share with twitter share with LinkedIn share with facebook
07/30/2020 | 03:16am EDT

By Adria Calatayud

 

AstraZeneca PLC said Thursday that its Tagrisso drug has been granted breakthrough therapy designation in the U.S. for patients with non-small cell lung cancer.

The designation from the U.S. Food and Drug Administration seeks to accelerate development and regulatory review of potential new medicines to address a significant unmet medical need, the British pharmaceutical giant said.

The decision was based on positive results from a phase 3 trial, where Tagrisso reduced the risk of disease recurrence or death by around 80%, AstraZeneca said.

The designation covers the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, AstraZeneca said.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
06:00aASTRAZENECA : Serum Institute to boost production of COVID-19 vaccine doses to 2..
RE
05:01aASTRAZENECA : Berenberg gives a Buy rating
MD
04:24aASTRAZENECA : JP Morgan reaffirms its Buy rating
MD
02:00aRussian scientist behind COVID-19 vaccine defends 'wartime' roll-out
RE
09/28China's Kangtai gets approval for clinical trial of coronavirus vaccine candi..
RE
09/28U.S. FDA pauses Inovio's coronavirus vaccine trial plan
RE
09/28GLOBAL MARKETS LIVE : TikTok, Apple, American Airlines…
09/28ASTRAZENECA : Italian firm developing AstraZeneca's COVID-19 vaccine might go pu..
RE
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/25Canada's biggest provinces seek clampdown on social gatherings as coronavirus..
RE
More news
Financials (USD)
Sales 2020 26 713 M - -
Net income 2020 3 103 M - -
Net Debt 2020 13 098 M - -
P/E ratio 2020 49,7x
Yield 2020 2,57%
Capitalization 144 B 144 B -
EV / Sales 2020 5,87x
EV / Sales 2021 5,14x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,68 $
Last Close Price 109,54 $
Spread / Highest target 41,9%
Spread / Average Target 8,35%
Spread / Lowest Target -39,7%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC11.86%143 516
JOHNSON & JOHNSON0.85%387 315
ROCHE HOLDING AG4.46%302 660
MERCK & CO., INC.-9.00%209 320
PFIZER, INC.-7.99%202 215
NOVARTIS AG-12.09%192 245